Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018

Background Data from randomized controlled trials and observational studies on older adults who take statins for primary prevention of atherosclerotic cardiovascular disease are limited. To determine the incidence of statin use in older adults with and without cardiovascular disease (CVD) and/or diabetes (DM), we conducted a descriptive observational study. Methods The cohort consisted of health plan members in the NIH Collaboratory Distributed Research Network aged >75 years who had continuous drug and medical benefits for ≥183 days during the study period, January 1, 2008- March 31, 2018. We defined DM and CVD using diagnosis codes, and identified statins using dispensing data. Statin use was considered incident if a member had no evidence of statin exposure in the claims during the previous 183 days, and the use was considered long-term if statins were supplied for ≥180 days. Incidence rates were reported among members with and without CVD and/or diabetes, and stratified by year, sex, and age group. Results Among 757,569 eligible members, 109,306 older adults initiated statins and 54,624 became long-term users. Health plan members with CVD had the highest incidence of statin use (143.9 initiators per 1,000 member-years for CVD & DM; 114.5 initiators per 1,000 member-years for CVD & No DM). Among health plan members without CVD, those with DM had rates of statin use that were over two times higher than members without DM (76.1 versus 34.5 initiators per 1,000 member-years, respectively). Statin initiation remained steady throughout 2008–2016, was slightly higher in males, and declined with increasing age. Conclusion Incidence of statin use varied by CVD and DM comorbidity, and was lowest among those without CVD. These results highlight the potential clinical equipoise to conduct large pragmatic clinical trials to generate evidence that could be used to inform future blood cholesterol guidelines.

[1]  G. Corrao,et al.  Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[2]  Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England , 2015, BMJ Open.

[3]  K. Watson,et al.  The 2013 ACC/AHA Cholesterol Treatment Guidelines: Applicability to Patients with Diabetes , 2016, Current Diabetes Reports.

[4]  G. Lippi,et al.  Statins for Primary Prevention of Cardiovascular Disease. , 2017, Trends in pharmacological sciences.

[5]  Yitzchak Weinberger,et al.  Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines , 2015, Drugs & Aging.

[6]  M. Reichman,et al.  Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study , 2017, Diabetes Care.

[7]  Statin Use in Very Elderly Individuals, 1999-2012. , 2015, JAMA internal medicine.

[8]  Richard Ofori-Asenso,et al.  Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis , 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

[9]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[10]  R. Huupponen,et al.  Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes , 2016, Pharmacoepidemiology and drug safety.

[11]  S. Yusuf,et al.  Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials. , 2017, Circulation.

[12]  J. Coste,et al.  Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France , 2019, European heart journal.

[13]  Eric A. Miller,et al.  Characteristics of Medicare Advantage and Fee-for-Service Beneficiaries Upon Enrollment in Medicare at Age 65 , 2016, The Journal of ambulatory care management.

[14]  Sengwee Toh,et al.  Early impact of the ICD‐10‐CM transition on selected health outcomes in 13 electronic health care databases in the United States , 2018, Pharmacoepidemiology and drug safety.

[15]  Paul M. Ridker,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[16]  C. Roumie,et al.  Validation of an algorithm to identify heart failure hospitalisations in patients with diabetes within the veterans health administration , 2018, BMJ Open.

[17]  D. Bereczki,et al.  The Cochrane Database of Systematic Reviews , 2003 .

[18]  A. Go,et al.  Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence. , 2016, JAMA.

[19]  S. Yusuf,et al.  Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[20]  Michael P. Ho,et al.  Adherence to Statins in Primary Prevention: Yearly Adherence Changes and Outcomes , 2014, Journal of managed care pharmacy : JMCP.

[21]  J. Gurwitz,et al.  A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data , 2012, Pharmacoepidemiology and drug safety.

[22]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[23]  ScienceDirect Nutrition, metabolism, and cardiovascular diseases : NMCD. , 1991 .

[24]  Alexander Turchin,et al.  Accuracy of Electronically Reported “Meaningful Use” Clinical Quality Measures , 2013, Annals of Internal Medicine.

[25]  R. Ofori-Asenso,et al.  Predictors of first‐year nonadherence and discontinuation of statins among older adults: a retrospective cohort study , 2018, British journal of clinical pharmacology.

[26]  V. Jamdade,et al.  Statin use and the risk of developing diabetes: a network meta‐analysis , 2016, Pharmacoepidemiology and Drug Safety.

[27]  J. Tu,et al.  Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes , 2002 .